ONWARD MEDICAL BV EO -12 - Asset Resilience Ratio
ONWARD MEDICAL BV EO -12 (63E) has an Asset Resilience Ratio of 16.01% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 63E current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2022)
This chart shows how ONWARD MEDICAL BV EO -12's Asset Resilience Ratio has changed over time. See net assets of ONWARD MEDICAL BV EO -12 for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ONWARD MEDICAL BV EO -12's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ONWARD MEDICAL BV EO -12 (63E) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €7.50 Million | 16.01% |
| Total Liquid Assets | €7.50 Million | 16.01% |
Asset Resilience Insights
- Good Liquidity Position: ONWARD MEDICAL BV EO -12 maintains a healthy 16.01% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
ONWARD MEDICAL BV EO -12 Industry Peers by Asset Resilience Ratio
Compare ONWARD MEDICAL BV EO -12's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 33.70% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392 |
Biotechnology | 11.64% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 2.21% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
Annual Asset Resilience Ratio for ONWARD MEDICAL BV EO -12 (2022–2022)
The table below shows the annual Asset Resilience Ratio data for ONWARD MEDICAL BV EO -12.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 26.11% | €20.00 Million ≈ $23.38 Million |
€76.59 Million ≈ $89.55 Million |
-- |
About ONWARD MEDICAL BV EO -12
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company engages in developing ARCEX, a technology to enhance hand strength and sensation for individuals with SCI; ARCIM, a spinal cord stimulation system designed to address blood pressure instability and other symptoms in people wit… Read more